Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Top

17-09-2018 | Rheumatoid arthritis | Article

Low persistence rates in rheumatoid arthritis patients treated with triple therapy are attributed to adverse drug events associated with sulfasalazine

print
PRINT
insite
SEARCH

Erhardt DP et al. Arthritis Care Res (Hoboken) 2018. doi: 10.1002/acr.23759

Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.

https://doi.org/10.1002/acr.23759

print
PRINT
Image Credits